Cheng Zhao

Dr. Cheng Zhao


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2024 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
SLShuao Li
Shuao Li
Ningning HeNingning He
Ningning He
XWXiaoyu Wu
Xiaoyu Wu
FCFang Chen
Fang Chen
QXQingwen Xue
Qingwen Xue
CZCheng Zhao
Cheng Zhao
Sonodynamic therapy (SDT) utilizes specific sound waves to activate sonosensitizers, generating localized biological effects to eliminate tumor cells. With advancements in nanomedicine, the application of nano-acoustic sensitizers has significantly advanced the development of SDT. BaTiO3 (BTO), an inorganic nano-acoustic sensitizer, possesses light refraction characteristics and a high dielectric constant, and can generate an electric field under ultrasound (US) stimulation. With continuous progress in multidisciplinary fields of US research, scientists have developed various types of barium titanate nanoparticles (BTNPs) to further advance SDT research and applications in tumor therapy. In this review, we present recently proposed and representative BTNPs, including their pathways of action, such as the induction of tumor cell senescence, ferroptosis, and glutathione depletion to reshape the tumor microenvironment, as well as their surface modifications. Research indicates that the mechanisms of action of ultrasound-driven BTNPs in tumor therapy are multifaceted. These mechanisms, whether utilized individually or synergistically, offer a potent and targeted strategy for cancer treatment. Furthermore, we discuss the application of BTNPs in various tumor types. Finally, we summarize the current challenges and future prospects for the clinical translation of BTNPs.

29 October 2023 in Life Sciences
Verified
Journal Article
Closed access
FCFang Chen
Fang Chen
QXQingwen Xue
Qingwen Xue
NHNingning He
Ningning He
XZXuehui Zhang
Xuehui Zhang
SLShangyong Li
Shangyong Li
CZCheng Zhao
Cheng Zhao

16 July 2025 in BMC Cancer
Verified
Journal Article
Open access
PDF file
YFYanan Feng
Yanan Feng
YCYanjie Chen
Yanjie Chen
QWQiong Wu
Qiong Wu
ZBZhenghao Bao
Zhenghao Bao
CNChunping Ning
Chunping Ning
CZCheng Zhao
Cheng Zhao
Although struma ovarii (SO) is mostly benign, it is frequently overtreated due to challenges in differentiating it from malignant tumors. Therefore, the purpose of this study was to investigate the clinical, laboratory, ultrasonographic, and pathological characteristics of SO to improve the accuracy of preoperative diagnosis. We retrospectively reviewed the clinical data and imaging characteristics of 103 patients with postoperative pathology for SO at the Affiliated Hospital of Qingdao University from May 2013 to November 2023. Among the 103 patients diagnosed with SO, 95 were benign SO (median age: 44.9 years (range, 15–83 years)) and 8 were malignant struma ovarii (MSO) (49.6 years (range, 15–83 years)), malignant cases accounted for 7.8% of the cohort. No statistically significant difference was observed in the median age between patients with benign SO and those with MSO (p = 0.346). Approximately 52.4% of SO patients had an increase in CA125, while CEA, AFP, HE4 and CA199 were basically within the normal range, and these markers had no clinical significance. The ultrasound manifestations were mostly cystic masses or predominantly cystic-solid masses (78/98), and 18 cases were solid masses or predominantly solid-cystic masses. Two patients showed negative results on ultrasound examination and was discovered during another gynecological surgery. Most of the masses are completely separated and multilocular, most with smooth outer margins. Nearly one-half of the masses have punctate or short-line echoes with comet tails, papillary protrusions can be seen on the inner wall of some lesions, and there is usually no blood flow inside the tumor or only a few dotted blood flow signals (79/96). Among the 6 patients with MSO which have ultrasound imaging, 4 patients showed a multilocular cystic mass on ultrasound, with poor sound echo in the cystic part, and 2 patients showed a solid mass on ultrasound with abundant blood flow signals. Immunohistochemistry results showed positive expression rates for thyroid transcription factor-1 (TTF-1) (96%, 24/25), thyroglobulin (TG) (90.5%, 19/21), PAX8 (94.7%, 18/19), and Ki-67 (100% 16/16), though Ki-67 expression levels were generally low, with 15 cases < 5% and 1 case at 50%. Ultrasonographic features-including multilocular cystic-solid masses with septations, hyperechoic “pearl signs,” and comet-tail artifacts-may raise suspicion for SO. However, differentiating between benign and malignant cases remains challenging due to significant imaging overlap. A multimodal diagnostic approach incorporating clinical presentation, laboratory findings, and histopathological evaluation is essential for accurate diagnosis and optimal management.

25 May 2026 in Ultrasound in Medicine & Biology
Verified
Journal Article
Closed access
HLHang Li
Hang Li
XNXiaoyan Niu
Xiaoyan Niu
HYHui Yang
Hui Yang
SWSai Wu
Sai Wu
XTXiaojuan Tian
Xiaojuan Tian
CZCheng Zhao
Cheng Zhao